New shot could tame birch pollen allergies, early trial hopes

NCT ID NCT07254871

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether an injection called DM-101PX can reduce nasal symptoms caused by birch pollen allergy. About 100 adults with birch pollen allergic rhinitis or rhinoconjunctivitis will receive either the drug or a placebo. The main goal is to see if the treatment lowers symptom scores during a nasal allergen challenge.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

DM-101PX (a biologic injection)

What this could lead to

If it works, this could lead to a new treatment that eases nasal allergy symptoms during birch pollen season.

What could go wrong

This is an early Phase 2 trial with only 100 people, so results may not hold up in larger studies. The treatment is still experimental and may not work better than placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIRCH POLLEN ALLERGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

seasonal allergic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Locations

  • Cliantha Research

    Mississauga, Ontario, ON L4W 1A4, Canada